QLT reported a net loss of $6.2 million for the quarter ended June 30, an improvement over the $16.3 million net loss the company reported in the same quarter during 2012, according to a news release.During the quarter, QLT cut research and development…
Chances are, the eye surgeons who are most drawn to this blog about the business side of ophthalmology are competitive and financially driven. It’s for precisely this reason I’d like to take a brief two-blog recess from counting your practice’s numbers and urge you, instead, to consider whether the quality of your life — in and out of practice — is adding up. Are there other more important dimensions of success that your quest for financial success in your practice is edging out? This is a question I ask clients (Read more...)
The human brain has 100 billion neurons, connected to each other in networks that allow us to interpret the world around us, plan for the future, and control our actions and movements. MIT neuroscientist Sebastian Seung wants to map those networks, cre…
Researchers have achieved dynamic, atomic-scale views of a protein needed to maintain the transparency of the lens in the human eye. The work, funded in part by the National Institutes of Health, could lead to new insights and drugs for treating catara…
Researchers in Taiwan have discovered that people with sleep apnea are far more likely to develop glaucoma compared to those without the sleep condition. The results of this study, which is the first to calculate the risk of the disease among people wi…
Regeneron Pharmaceuticals Inc’s Eylea (aflibercept) significantly improved vision in patients with diabetic macular edema (DME) compared to laser surgery in two late-stage clinical trials. Reuters Health Information